ADMA Biologics (ADMA) Scheduled to Post Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA) will be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect ADMA Biologics to post earnings of $0.05 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The firm had revenue of $73.90 million during the quarter, compared to analysts’ expectations of $73.50 million. On average, analysts expect ADMA Biologics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Price Performance

ADMA opened at $6.91 on Wednesday. The stock has a 50-day moving average price of $6.27 and a 200-day moving average price of $5.06. ADMA Biologics has a 12-month low of $3.06 and a 12-month high of $6.97. The company has a current ratio of 5.16, a quick ratio of 1.69 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $1.58 billion, a P/E ratio of -53.15 and a beta of 0.43.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 49,887 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $6.01, for a total transaction of $299,820.87. Following the completion of the transaction, the director now owns 2,527,500 shares of the company’s stock, valued at approximately $15,190,275. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 639,895 shares of company stock valued at $3,927,169 in the last 90 days. Insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ADMA. HC Wainwright reissued a “buy” rating and issued a $7.50 target price (up previously from $6.00) on shares of ADMA Biologics in a research note on Tuesday, March 26th. Mizuho boosted their target price on ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Cantor Fitzgerald boosted their target price on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $7.88.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.